stockrow
Saturday 7 November 2026
Export GENB’s income statement to Excel — free account
Generate Biomedicines, Inc.
GENB Healthcare Biotechnology
Generate Biomedicines, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $31.9 million, up 55.9% from fiscal 2024.
13.06
0.49
+3.90%
Follow GENB
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 20 | 32 | 32 | +55.9% | 30 | 24 | 92 | +42.5% | |
| Gross margin, % | — | — | — | — | — | — | — | — | 100.00 | 100.00 | 100.00 | 0.0 pt | ||||||
| EBT | — | — | — | — | — | — | — | — | (181) | (223) | (230) | +23.0% | ||||||
| EBT margin, % | — | — | — | — | — | — | — | — | (885.54) | (698.59) | (707.52) | +186.9 pt | ||||||
| Net income | — | — | — | — | — | — | — | — | (181) | (223) | (409) | +22.9% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | — | 0.64 | 0.97 | 0.25 | +51.7% | |||||
| Earnings | — | — | — | — | — | — | — | — | (6.66) | (7.57) | (5.15) | +13.7% | ||||||
| Cash flow | — | — | — | — | — | — | — | — | (3.67) | (6.08) | (3.02) | +65.8% | ||||||
| Capex | — | — | — | — | — | — | — | — | (0.11) | (0.11) | (1.26) | (0.5%) | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (3.78) | (6.19) | (4.29) | +63.9% | ||||||
| Book value | — | — | — | — | — | — | — | — | (13.54) | (18.68) | 3.56 | +37.9% | ||||||
| Shares, m | — | — | — | — | — | — | — | — | 32 | 33 | 65 | +2.8% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 51.24 | 0.0 | ||||||
| P/B | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 3.65 | 0.0 | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 37.20 | 0.0 | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | (0.46) | (0.46) | (2.20) | (0.5) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | — | (118) | (201) | (388) | +70.4% | |||||
| Capex | — | — | — | — | — | — | — | — | (3) | (4) | (162) | +2.2% | ||||||
| Free cash flow | — | — | — | — | — | — | — | — | (121) | (204) | (550) | +68.4% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | — | 321 | 152 | 414 | (52.6%) | |||||
| Net debt | — | — | — | — | — | — | — | — | (389) | (219) | (456) | (43.7%) | ||||||
| Shareholders’ equity | — | — | — | — | — | — | — | — | (435) | (616) | 456 | +41.8% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | — | 0.00 | (58.82) | (90.35) | (58.8) pt | |||||
| ROIC | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | — | — | — | — | — | — | 0.00 | 47.51 | 0.00 | +47.5 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | — | — | 312 | — | — | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | — | 0.00 | 0.10 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
Generate Biomedicines, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| LYCA Lycia Therapeutics Inc. | $1.7B | — | — | — | — | — | — | — | Compare |
| NRIX Nurix Therapeutics, Inc. | $1.6B | 6.1× | 5.5× | +8,426.27% (above 0%: growing) | n/m | +1,122.10% (above 0%: growing) | 100.00% | 83.12% | Compare |
| GENB Generate Biomedicines, Inc. | $1.6B | — (loss-making) | — (loss-making) | — | n/m | −224.24% (below 0%: shrinking) | 100.00% | (1,134.21%) | |
| ABSI Absci Corporation | $1.6B | — (loss-making) | — (loss-making) | −46.37% (below 0%: shrinking) | n/m | −71.74% (below 0%: shrinking) | 100.00% | (10,741.51%) | Compare |
| NVAX Novavax, Inc. | $1.6B | — (loss-making) | 110× | −3.05% (below 0%: shrinking) | n/m | −189.09% (below 0%: shrinking) | 65.61% | (45.80%) | Compare |
| SLS SELLAS Life Sciences Group, Inc. | $1.6B | — (loss-making) | — (loss-making) | −57.10% (below 0%: shrinking) | n/m | −3.52% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| KLRA Kailera Therapeutics, Inc. | $1.6B | — (loss-making) | — | — | n/m | −325.95% (below 0%: shrinking) | — | 0.00% | Compare |
| BRVE Braveheart Bio, Inc. | $1.6B | — | — | — | n/m | — | — | 0.00% | Compare |
| NTLA Intellia Therapeutics, Inc. | $1.6B | — (loss-making) | — (loss-making) | −48.03% (below 0%: shrinking) | n/m | −11.05% (below 0%: shrinking) | 100.00% | (1,707.73%) | Compare |
| Median of peers | $1.6B | — | — | −46.37% | — | −41.40% | 100.00% | 0.00% |
Generate Biomedicines, Inc. (GENB) Latest News
No news at this impact. Lower the threshold for more.